# Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

> **NCT02754167** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Pieris Pharmaceuticals GmbH** · enrollment: 24 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **BIOLOGICAL:** PRS-080#022-DP
- **BIOLOGICAL:** PRS-080-Placebo#001

## Key facts

- **NCT ID:** NCT02754167
- **Lead sponsor:** Pieris Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-06
- **Primary completion:** 2017-02-06
- **Final completion:** 2017-12-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754167, "Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02754167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*